Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates

BACKGROUND: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunningham, Jacobi I, Eyerman, David J, Todtenkopf, Mark S, Dean, Reginald L, Deaver, Daniel R, Sanchez, Connie, Namchuk, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764014/
https://www.ncbi.nlm.nih.gov/pubmed/31294646
http://dx.doi.org/10.1177/0269881119856850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764014/
https://www.ncbi.nlm.nih.gov/pubmed/31294646
http://dx.doi.org/10.1177/0269881119856850

Ejemplares similares